Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
Discussions on the handling of the de-facto cap in social security spending in this year’s “honebuto” policy paper are hitting a critical juncture, with the ruling Liberal Democratic Party’s (LDP) health affairs panel stepping up its calls for scrapping the…
To read the full story
Related Article
- Japan OKs FY2024 Budget Ceilings, 520 Billion Yen for Social Security Cost Rise
July 26, 2023
- Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
- Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
June 8, 2023
- Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
June 7, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
REGULATORY
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…